Health-care companies ticked down as enthusiasm about a new class of weight-loss drugs continued to wane.

Viking Therapeutics slid, giving up initial gains, after the biotech posted data on its oral weight-loss drug showing better-than-expected results in an early-stage trial.

Similarly, Anglo-Swedish drug giant AstraZeneca said its entry in the glucagon-like peptide agonist class was well tolerated by patients in an early-stage clinical trial.

Shares of first movers in the GLP-1 class, Novo Nordisk and Eli Lilly, continued their recent retreat.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

11-04-24 1800ET